It is one of the biggest medical technologies sector investments in Spain and is directed to finalize the development of a blood pressure measurer which does not require calibration and does not need a bracelet.
They have recently closed distribution deals with companies from the medical sectors in these two countries. Avinent’s turnover in 2009 totaled 4.2 million euros and is expected to reach 6 million euros by the end of this year.
Intelligent Pharma, Neurotec Pharma, SOM Biotech, Palo Biofarma and the Barcelona Science Park have decided to create a research consortium to join forces and technology to design new multiple sclerosis (MS) therapies.
Over the next three years, they will carry out a number of projects to support the start up of new companies in the life sciences field, identify new private investors and attract international investors.